Amelioration of established experimental autoimmune encephalomyelitis by an MHC anchor-substituted variant of proteolipid protein 139-151

Journal of Immunology

Volumn 174, Issue 6, 2005, Pages 3352-3358

  Margot, Carrie D ^a   Ford, Mandy L ^a   Evavold, Brian D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2; MHC ANCHOR SUBSTITUTED PEPTIDE; MYELIN PROTEIN; PEPTIDE 145D; PROTEOLIPID PROTEIN; PROTEOLIPID PROTEIN[139-151]; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SUBSTITUTION; ANAPHYLACTIC SHOCK; ANIMAL CELL; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CLONAL ANERGY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HYPERSENSITIVITY REACTION; IMMUNIZATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL LINE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN VARIANT; T LYMPHOCYTE SUBPOPULATION;

EID: 14844346786     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.6.3352     Document Type: Article

References (43)

1. Steinman, L. 1996. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85:299.
2. Kuchroo, V. K., A. C. Anderson, H. Waldner, M. Munder, E. Bettelli, and L. B. Nicholson. 2002. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu. Rev. Immunol. 20:101.
3. Brown, A. M., and D. E. McFarlin. 1981. Relapsing experimental allergic encephalomyelitis in the SJL/J mouse. Lab. Invest. 45:278.
4. Tuohy, V. K., Z. Lu, R. A. Sobel, R. A. Laursen, and M. B. Lees. 1989. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J. Immunol. 142:1523.
5. Sobel, R. A., V. K. Tuohy, Z. J. Lu, R. A. Laursen, and M. B. Lees. 1990. Acute experimental allergic encephalomyelitis in SJL/J mice induced by a synthetic peptide of myelin proteolipid protein. J. Neuropathol. Exp. Neurol. 49:468.
6. Williams, K. C., and W. F. Hickey. 1995. Traffic of hematogenous cells through the central nervous system. Curr. Top. Microbiol. Immunol. 202:221.
7. Nicholson, L. B., J. M. Greer, R. A. Sobel, M. B. Lees, and V. K. Kuchroo. 1995. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 2:397.
8. Nicholson, L. B., A. Murtaza, B. P. Hafler, A. Sette, and V. K. Kuchroo. 1997. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. Proc. Natl. Acad. Sci. USA 94:9279.
9. Sloan-Lancaster, J., and P. M. Allen. 1996. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol. 14:1.
10. Evavold, B. D., and P. M. Allen. 1991. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 252:1308.
11. Kappos, L., G. Comi, H. Panitch, J. Oger, J. Antel, P. Conlon, and L. Steinman. 2000. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial: the Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 6:1176.
12. Bielekova, B., B. Goodwin, N. Richert, I. Cortese, T. Kondo, G. Afshar, B. Gran, J. Eaton, J. Antel, J. A. Frank, et al. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6:1167.
13. Ford, M. L., and B. D. Evavold. 2003. Regulation of polyclonal T cell responses by an MHC anchor-substituted variant of MOG 35-55. J. Immunol. 171:1247.
14. Anderton, S. M., S. P. Manickasingham, C. Burkhart, T. A. Luckcuck, S. J. Holland, A. G. Lamont, and D. C. Wraith. 1998. Fine specificity of the myelin-reactive T cell repertoire: implications for TCR antagonism in autoimmunity. J. Immunol. 161:3357.
15. Anderton, S. M., S. Kissler, A. G. Lamont, and D. C. Wraith. 1999. Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells. Eur. J. Immunol. 29:1850.
16. Sloan-Lancaster, J., B. D. Evavold, and P. M. Allen. 1993. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363:156.
17. + T cell anergy in vitro. J. Exp. Med. 187:89.
18. Ryan, K. R., L. K. McNeil, C. Dao, P. E. Jensen, and B. D. Evavold. 2004. Modification of peptide interaction with MHC creates TCR partial agonists. Cell Immunol. 227:70.
19. Kuchroo, V. K., J. M. Greer, D. Kaul, G. Ishioka, A. Franco, A. Sette, R. A. Sobel, and M. B. Lees. 1994. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J. Immunol. 153:3326.
20. Kuchroo, V. K., R. A. Sobel, T. Yamamura, E. Greenfield, M. E. Dorf, and M. B. Lees. 1991. Induction of experimental allergic encephalomyelitis by myelin proteolipid-protein-specific T cell clones and synthetic peptides. Pathobiology 59:305.
21. Sloan-Lancaster, J., B. D. Evavold, and P. M. Allen. 1994. Th2 cell clonal anergy as a consequence of partial activation. J. Exp. Med. 180:1195.
22. Lafaille, J. J., F. V. Keere, A. L. Hsu, J. L. Baron, W. Haas, C. S. Raine, and S. Tonegawa. 1997. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 186:307.
23. Anderson, A. C., L. B. Nicholson, K. L. Legge, V. Turchin, H. Zaghouani, and V. K. Kuchroo. 2000. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: mechanisms of selection of the self-reactive repertoire. J. Exp. Med. 191:761.
24. Klein, L., M. Klugmann, K. A. Nave, V. K. Tuohy, and B. Kyewski. 2000. Shaping of the autoreactive T-cell repertoire by a splice variant of self protein expressed in thymic epithelial cells. Nat. Med. 6:56.
25. Pedotti, R., D. Mitchell, J. Wedemeyer, M. Karpuj, D. Chabas, E. M. Hattab, M. Tsai, S. J. Galli, and L. Steinman. 2001. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat. Immunol. 2:216.
26. Vergelli, M., B. Hemmer, U. Utz, A. Vogt, M. Kaibus, L. Tranquill, P. Conlon, N. Ling, L. Steinman, H. F. McFarland, and R. Martin. 1996. Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99). Eur. J. Immunol. 26:2624.
27. Harrington, C. J., A. Paez, T. Hunkapiller, V. Mannikko, T. Brabb, M. Ahearn, C. Beeson, and J. Goverman. 1998. Differential tolerance is induced in T cells recognizing distinct epitopes of myelin basic protein. Immunity 8:571.
28. Greer, J. M., R. A. Sobel, A. Sette, S. Southwood, M. B. Lees, and V. K. Kuchroo. 1996. Immunogenic and encephalitogentc epitope clusters of myelin proteolipid protein. J. Immunol. 156:371.
29. Forsthuber, T. G., C. L. Shive, W. Wienhold, K. de Graaf, E. G. Spack, R. Sublett, A. Melms, J. Kort, M. K. Racke, and R. Weissert. 2001. T cell epitopes of human myelin oligodendrocyte glycoprotein identified in HLA-DR4 (DRB1*0401) transgenic mice are encephalitogenic and are presented by human B cells. J. Immunol. 167:7119.
30. Wucherpfennig, K. W., A. Sette, S. Southwood, C. Oseroff, M. Matsui, J. L. Strominger, and D. A. Hafler. 1994. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J. Exp. Med. 179:279.
31. Racke, M. K., A. Bonomo, D. E. Scott, B. Cannella, A. Levine, C. S. Raine, E. M. Shevach, and M. Rocken. 1994. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J. Exp. Med. 180:1961.
32. Ebers, G. C., K. Kukay, D. E. Bulman, A. D. Sadovnick, G. Rice, C. Anderson, H. Armstrong, K. Cousin, R. B. Bell, W. Hader, et al. 1996. A full genome search in multiple sclerosis. Nat. Genet. 13:472.
33. Haines, J. L., M. Ter-Minassian, A. Bazyk, J. F. Gusella, D. J. Kim, H. Terwedow, M. A. Pericak-Vance, J. B. Rimmler, C. S. Haynes, A. D. Roses, et al. 1996. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex: the Multiple Sclerosis Genetics Group. Nat. Genet. 13:469.
34. Goris, A., S. Sawcer, K. Vandenbroeck, H. Carton, A. Billiau, E. Setakis, A. Compston, and B. Dubois. 2003. New candidate loci for multiple sclerosis susceptibility revealed by a whole genome association screen in a Belgian population. J. Neuroimmunol. 143:65.
35. Harbo, H. F., P. Datta, A. Oturai, L. P. Ryder, S. Sawcer, E. Setakis, E. Akesson, E. G. Celius, H. Modin, M. Sandberg-Wollheim, et al. 2003. Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients. J. Neuroimmunol. 143:101.
36. Khare, M., M. Rodriguez, and C. S. David. 2003. HLA class II transgenic mice authenticate restriction of myelin oligodendrocyte glycoprotein-specific immune response implicated in multiple sclerosis pathogenesis. Int. Immunol. 15:535.
37. Johnson, K. P., B. R. Brooks, J. A. Cohen, C. C. Ford. J. Goldstein, R. P. Lisak, L. W. Myers, H. S. Panitch, J. W. Rose, and R. B. Schiffer. 1995. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial: the Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268.
38. Shukaliak Quandt, J., E. Borras, E. Prat, H. Gelderblom, R. A. Houghten, A. Kashani, C. Pinilla, C. S. Stuerzebecher, and R. Martin. 2004. Peptidic complex mixtures as therapeutic agents in CNS autoimmunity. Mol. Immunol. 40:1075.
39. Teitelbaum, D., A. Meshorer, T. Hirshfeld, R. Arnon, and M. Sela. 1971. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1:242.
40. Teitelbaum, D., M. Fridkis-Hareli, R. Arnon, and M. Sela. 1996. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 64:209.
41. Teitelbaum, D., R. Arnon, and M. Sela. 1999. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Proc. Natl. Acad. Sci. USA 96:3842.
42. Aharoni, R., D. Teitelbaum, M. Sela, and R. Arnon. 1997. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 94:10821.
43. Aharoni, R., D. Teitelbaum, M. Sela, and R. Arnon. 1998. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J. Neuroimmunol. 91:135.